News & Links

November 2009 - Britannia Pharmaceuticals has previously taken apomorphine nasal powder through to phase III clinical trials in patients with Parkinson’s disease. In these trials apomorphine nasal powder demonstrated clinical efficacy in relieving the ‘off’ periods of the mid to late stages of disease. Unfortunately the trials were stopped due to patient withdrawals as a result of reversible local irritation in the lower nostril.

Currently Britannia Pharmaceuticals has stopped development of apomorphine nasal powder but is interested to hear from parties that have a nasal delivery device that could prevent the accumulation of powder in the lower nose.

December 2009 - APO-hub launched. The hub for our apomorphine product has gone live at www.apo-hub.com, detailing what apomorphine is and basic information on Parkinson's Disease.